Cytori and BARDA amend contract for development of thermal burn cell therapy
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 6:45AM CST
CYTX: 0.48 (-0.01)
Cytori and BARDA Amend Contract Option to Accelerate the Advancement of a Thermal Burn Injury Countermeasure
Business Wire - Fri Dec 19, 7:00AM CST
Cytori Therapeutics (NASDAQ: CYTX) today announced that the Company and Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services, executed an amendment of a contract option originally signed in August 2014 to fund continued investigation and development of Cytori Cell Therapy(TM) for use in thermal burn injuries.
CYTX: 0.48 (-0.01)
Cytori to Host an Informational Session on Its Planned U.S. STAR Pivotal Trial With Principal Investigator, Dr. Dinesh Khanna
Business Wire - Thu Dec 18, 4:39PM CST
Cytori Therapeutics, Inc. (NASDAQ:CYTX) announces it will be hosting an information session dedicated to its planned STAR pivotal trial and scleroderma, featuring principal investigator Dr. Dinesh Khanna. The session will be held on January 14, 2015, from 1:30 PM to 4:30 PM at the Prescott Hotel, 545 Post Street, San Francisco, Room 736.
CYTX: 0.48 (-0.01)
Stock to Watch: Cytori Therapeutics Up 5.7% (CYTX)
Comtex SmarTrend(R) - Thu Dec 18, 12:48PM CST
Cytori Therapeutics (NASDAQ:CYTX) is one of today's best performing penny stocks, up 5.7% to $0.52 on 1.0x average daily volume. Thus far today, Cytori Therapeutics has traded 1.6 million shares, vs. average volume of 1.5 million shares per day. The stock has outperformed the Dow (5.7% to the Dow's 1.7%) and outperformed the S&P 500 (5.7% to the S&P's 1.8%) during today's trading.
CYTX: 0.48 (-0.01)
Biotech Stocks Technical Insight -- ARIAD Pharma, Geron, PDL BioPharma, Cytori Therapeutics, and Navidea Biopharma
PR Newswire - Thu Dec 18, 8:15AM CST
Investor-Edge has initiated coverage on the following equities: ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Geron Corporation (NASDAQ: GERN), PDL BioPharma Inc. (NASDAQ: PDLI), Cytori Therapeutics Inc. (NASDAQ: CYTX), and Navidea Biopharmaceuticals Inc. (NYSE MKT: NAVB). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Wednesday, December 17, 2014, surged as the Dow Jones Industrial Average finished at 17,356.87, up 1.69% and the NASDAQ Composite closed at 4,644.31, up 2.12%. The S&P 500 finished the session 2.04% higher at 2,012.89. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Index ended the day at 791.66, up 1.90%, with the index advancing 6.28% in the previous three months. Register for your complimentary reports on these five stocks at:
NAVB: 2.00 (+0.02), CYTX: 0.48 (-0.01), GERN: 3.06 (+0.05), ARIA: 6.81 (+0.15), PDLI: 7.61 (unch)
Global Regenerative Medicine Market: 20.16% CAGR to 2019 Forecasts a New Research Report at ReportsnReports.com
PRWeb - Wed Dec 17, 10:30PM CST
The rise in prevalence of degenerative diseases is one of the main factors which is driving the growth of the global regenerative medicine market. Regenerative medicine is involved in the process of replacing or regenerating human tissues, cells and/or organs for normal functioning of the body. Small molecules and biologics, gene therapy, and cell therapy are the three main technologies which are used in regenerative medicine. The global market is expected to grow at a compound annual growth rate of 20.16% during the period from 2014 to 2019. Increase in demand for regenerative products and an increase in research and development are also fueling the growth in the global regenerative medicine market.
RTIX: 5.20 (unch), MDT: 74.08 (+0.31), PSTI: 2.46 (unch), OSIR: 14.87 (+0.13), OPXA: 0.80 (+0.01), FCSC: 2.38 (+0.04), BAX: 74.45 (-0.04), CYTX: 0.48 (-0.01)
Cytori to Provide Corporate Update at 2015 Biotech Showcase(TM) in San Francisco
Business Wire - Wed Dec 17, 6:25PM CST
Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that the company has been selected to present at the Biotech Showcase(TM) at 3:30 PM Pacific Time (6:30 PM Eastern Time) on Monday, January 12, 2015. The presentation will take place in the C-Mission II room at the Parc 55 Wyndham Hotel in San Francisco.
CYTX: 0.48 (-0.01)
Cytori Therapeutics Up 6.2%, Penny Stock Attracts Attention (CYTX)
Comtex SmarTrend(R) - Wed Dec 10, 10:05AM CST
Cytori Therapeutics (NASDAQ:CYTX) is one of today's best performing penny stocks, up 6.2% to $0.49 on 2.1x average daily volume. Thus far today, Cytori Therapeutics has traded 3.0 million shares, vs. average volume of 1.4 million shares per day. The stock has outperformed the Dow (7.3% to the Dow's -0.6%) and outperformed the S&P 500 (7.3% to the S&P's -0.5%) during today's trading.
CYTX: 0.48 (-0.01)
FDA Grants Cytori Conditional Approval for a U.S. Pivotal Clinical Trial in Scleroderma
Business Wire - Wed Dec 10, 7:01AM CST
Cytori Therapeutics, Inc. (NASDAQ:CYTX) today announced that the U.S. Food and Drug Administration (FDA) has granted conditional approval for an Investigational Device Exemption (IDE) for a pivotal clinical trial, named the 'STAR' trial, to evaluate Cytori Cell Therapy(TM) as a potential treatment for impaired hand function in scleroderma, a rare autoimmune disease affecting approximately 50,000 patients in the United States.
CYTX: 0.48 (-0.01)
Cytori Therapeutics' Investor Presentation Now Available for On-Demand Viewing
CNW Group - Fri Dec 05, 7:00AM CST
Cytori Therapeutics (NASDAQ: CYTX), today announced that the presentation and corporate update given on December 4 by President and CEO Marc Hedrick, M.D. is now available for on-demand viewing at VirtualInvestorConferences.com.
CYTX: 0.48 (-0.01)
Cytori says new Japanese regen laws should goose Celution sales
Seeking Alpha - at Seeking Alpha - Thu Dec 04, 12:14PM CST
CYTX: 0.48 (-0.01)
Cytori Expects New Japan Laws to Boost Adoption of Cytori Cell Therapy
Business Wire - Thu Dec 04, 7:01AM CST
Cytori Therapeutics, Inc. (NASDAQ: CYTX) today confirmed that two Japanese regenerative medicine laws, which went into effect on November 25, 2014, remove regulatory uncertainties and provide a clear path for the Company to commercialize and market Cytori Cell Therapy(TM) and its Celution(R) System under the Company's existing and planned regulatory approvals.
CYTX: 0.48 (-0.01)
Eight Companies Webcast Live to Investors, December 4th at VirtualInvestorConferences.com
CNW Group - Tue Dec 02, 7:29AM CST
CEOs and top executives to take questions in real-time during formal roadshow presentations as well as meet and "chat" in virtual trade booths
SMLR: 2.06 (-0.08), ONVO: 6.84 (+0.03), CYTX: 0.48 (-0.01), IAG: 2.41 (+0.06)
Global Regenerative Medicines Market 2014-2020 - Technology, Application and Geography Analysis of the $67 Billion Industry
M2 - Wed Nov 26, 5:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/bx37gm/global) has announced the addition of the "Global Regenerative Medicines Market 2014-2020 - Technology, Application and Geography Analysis of the $67 Billion Industry" report to their offering. The global regenerative medicine market will reach $ 67.6 billion by 2020 from $16.4 billion in 2013, registering a CAGR of 23.2% Regenerative medicines have the unique ability to repair, replace and regenerate tissues and organs, affected due to some injury, disease or due to natural aging process. These medicines are capable of restoring the functionality of cells and tissues. These medicines find applicability in wide range of degenerative disorders including dermatology, neurodegenerative diseases, cardiovascular and orthopedic applications. Researchers are engaged in developing technologies based on biologics, genes, somatic as well as stem cells. The factors driving growth of this market include advancements in stem cell therapy, significance of nanotechnology and increasing incidences of degenerative diseases. Stem cells have unique ability of proliferation and differentiation. These cells can differentiate into any cell lineage. This distinctive characteristic of stem cells has made them of significant importance in this field. Additionally, the utilization of nano-materials in wound care, drug delivery and immunomodulation is opening growth avenues for the regenerative medicine market. However, the stringent regulations and the high cost of treatment act as hindrance for the progress of this market. The increasing focus on stem cells, their applications and the emerging economies would all contribute to the growth of this market. The developing nations are adopting technological advancements at a rapid pace, which would aid in the expansion of this market throughout the globe. KEY BENEFITS - The report provides an evaluation of drivers and restraints in this market, which would affect its growth. An assessment of opportunities is given to understand the growth avenues - The technology segment helps in understanding the present technologies used in this market - The application segment describes the availability of product based on type of diseases and discusses the ongoing studies for other disorders - The segmentation based on geography helps in analyzing advancements in regenerative medicine market throughout the globe - The projections in the report are made by analyzing the current market trends and future market potential for the period of 2013-2020 - The key strategies adopted by the market players are discussed to provide an insight on the winning approaches followed by the companies - Porter's five forces analysis is used to assess the present industrial scenario to help stakeholders in making decisive moves Scope of the Report MARKET BY TECHNOLOGY - Small molecules and Biologics - Gene therapy - Cell therapy MARKET BY APPLICATION - Dermatology - Cardiovascular - CNS - Orthopedic - Dental - Others - Autoimmune disorders - Muscle regeneration - Ocular diseases Companies Mentioned - Advanced Cell Technology - Athersys Inc. - Cytomedix - Cytori Therapeutics - Genzyme - Kinetic Concepts - Mesoblast Ltd. - NuVasive - Shire pharmaceuticals - Stem Cells For more information visit http://www.researchandmarkets.com/research/bx37gm/global
CYTX: 0.48 (-0.01), ATHX: 1.30 (-0.03)
Cytori: Why This Undervalued Cell-Therapy Biotech Is A Buy
Biotech Value Finder - at Seeking Alpha - Tue Nov 25, 8:20PM CST
Summary Cytori Therapeutics (NASDAQ: CYTX ) stock price has been down relentlessly throughout the majority of 2014, a steep decline attributable to multiple factors including the clinical enrollment hold placed on its ATHENA and ATHENA II trials,...
CYTX: 0.48 (-0.01)
Cytori Announces Promising Results in a Feasibility Trial of Cytori Cell Therapy in Conjunction with Anterior Cruciate Ligament Repair
Business Wire - Fri Nov 21, 7:00AM CST
Cytori Therapeutics, Inc. (NASDAQ: CYTX) today reported positive results from a clinical study of Cytori Cell Therapy(TM) in anterior cruciate ligament (ACL) reconstruction of patients with ACL tears. The 6 month results from the first 20 patients with combination Cytori Cell Therapy and bone-patellar tendon-bone (BPTB) grafts were presented at the Barcelona Knee Symposium on November 20, 2014.
CYTX: 0.48 (-0.01)
Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast
PR Newswire - Thu Nov 20, 3:09PM CST
Cytori Therapeutics (NASDAQ: CYTX), today announced that President and CEO Marc Hedrick, M.D. will present live at VirtualInvestorConferences.com on December 4, 2014.
CYTX: 0.48 (-0.01)